Likewise, two separate analyses of data from US community oncology clinics both showed a striking increase in the proportion of patients receiving first- or second-line anti–PD-1/PD-L1 therapy for NSCLC after FDA approval [24, 25]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.